Clinical Trial: NCT06120166
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Status:
RECRUITINGPhase:
Early Phase 1| Lead Sponsor: | He Huang |
| Information Provided By: | Zhejiang University |
| Last Update Posted: | 2025-09-19 |
Study Overview
Brief Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Official Title
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r DLBCL Clinical Research
Conditions
Diffuse Large B-cell Lymphoma
Intervention / Treatment
- Drug: Metabolically Armed CD19 CAR-T cells
Other Study ID Numbers
- Meta10-19-003
Start Date (Actual)
2023-11-16
Primary Completion Date (Estimated)
2025-12-01
Study Completion Date (Estimated)
2026-04-05
Enrollment (Estimated)
18
Study Type
Interventional
Phase
Early Phase 1
| Lead Sponsor: | He Huang |
| Information Provided By: | Zhejiang University |
| Last Update Posted: | 2025-09-19 |
Study Overview
Brief Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Official Title
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r DLBCL Clinical Research
Conditions
Diffuse Large B-cell Lymphoma
Intervention / Treatment
- Drug: Metabolically Armed CD19 CAR-T cells
Other Study ID Numbers
- Meta10-19-003
Start Date (Actual)
2023-11-16
Primary Completion Date (Estimated)
2025-12-01
Study Completion Date (Estimated)
2026-04-05
Enrollment (Estimated)
18
Study Type
Interventional
Phase
Early Phase 1